Trial | NCT01832870  Report issue

Title

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    9
This is a clinical trial designed to quantify the immune response and determine the tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for patients with advanced prostate cancer.
Study Started
Apr 30
2013
Primary Completion
Feb 29
2016
Study Completion
Feb 29
2016
Last Update
Aug 24
2017

Drug sipuleucel-T

  • Other names: Provenge

Drug ipilimumab

  • Other names: Yervoy

Treatment Experimental

Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.

Criteria 

Inclusion Criteria:

Subjects with advanced prostate cancer who are eligible to receive sipuleucel-T in accordance with FDA approved labeling of sipuleucel-T
Subjects must understand and sign an informed consent form

Exclusion Criteria:

Subjects who are not eligible to receive sipuleucel-T
No Results Posted